Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gautam Patel

Hospitalist Matthews, NC Medical Doctor

NPI 1679764054 CMS profile 439480

1500 Matthews Township Pkwy, Matthews, NC 28105

Open in the dashboard

General payments

$8,891

484 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gautam Patel of Matthews, NC is reported in the CMS Open Payments database as having received $8,891 across 484 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $501 21
2024 General $698 32
2023 General $1,112 54
2022 General $1,179 63
2021 General $1,976 115
2020 General $1,325 79
2019 General $2,100 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gautam Patel
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Gautam Patel were reported at $501. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Gautam Patel Hospitalist median Middle half National median
2019 $2,100 $96 $28–$201 $163
2020 $1,325 $48 $19–$125 $114
2021 $1,976 $70 $23–$167 $132
2022 $1,179 $85 $27–$174 $149
2023 $1,112 $89 $30–$191 $160
2024 $698 $95 $29–$204 $164
2025 $501 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,152 73 payments
  2. Janssen Pharmaceuticals, Inc $1,148 60 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $937 44 payments
  4. Novartis Pharmaceuticals Corporation $886 40 payments
  5. Electromed, Inc. $872 50 payments
  6. AstraZeneca Pharmaceuticals LP $860 52 payments
  7. AbbVie, Inc. $503 26 payments
  8. Merck Sharp & Dohme Corporation $382 24 payments
  9. Otsuka America Pharmaceutical, Inc. $304 16 payments
  10. Philips Electronics North America Corporation $210 11 payments
  11. Other $1,638 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,891 484 payments
Products named General payments · program years 2019–2025
  1. XARELTO $1,148 60 payments
  2. ELIQUIS $1,025 67 payments
  3. SMARTVEST $711 42 payments
  4. ENTRESTO $617 29 payments
  5. TEFLARO $453 23 payments
  6. BRILINTA $435 26 payments
  7. DALVANCE $416 23 payments
  8. VYNDAQEL $371 24 payments
  9. SPIRIVA RESPIMAT $315 15 payments
  10. JARDIANCE $313 14 payments
  11. Other $4,398 237 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

222

Median for Hospitalist: 109

Drug cost

$9,890

Median for Hospitalist: $6,399

Branded share of claims

22.5%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 15 $8,757
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 23 $210
Doxycycline Hyclate Generic 19 $163
Pantoprazole Sodium Generic 27 $147
Cefdinir Generic 12 $140
Atorvastatin Calcium Generic 18 $95
Metoprolol Succinate Generic 14 $78
Prednisone Generic 24 $74
Amlodipine Besylate Generic 17 $67
Clopidogrel Clopidogrel Bisulfate Brand 12 $66

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$62,699

Medicare's payments for the services billed

Medicare patients

301

Average age 80

Services billed

908

165 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Chronic kidney disease 56%
Ischemic heart disease 54%
Heart failure 52%
Atrial fibrillation 50%
Depression 41%
Diabetes 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $165
$165 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $98
$98 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $83
$83 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $54
$54 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

484 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospitalist in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record